No connection

Search Results

ABBV vs LEGN

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
LEGN
Legend Biotech Corporation
BEARISH
Price
$18.16
Market Cap
$3.36B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
LEGN
--
Forward P/E
ABBV
15.42
LEGN
15.79
P/B Ratio
ABBV
-146.66
LEGN
3.35
P/S Ratio
ABBV
6.5
LEGN
3.26
EV/EBITDA
ABBV
15.27
LEGN
-48.64

Profitability

Gross Margin
ABBV
71.46%
LEGN
20.03%
Operating Margin
ABBV
35.5%
LEGN
-6.72%
Profit Margin
ABBV
4.0%
LEGN
-28.85%
ROE
ABBV
137.96%
LEGN
-29.06%
ROA
ABBV
9.59%
LEGN
-5.01%

Growth

Revenue Growth
ABBV
9.1%
LEGN
64.2%
Earnings Growth
ABBV
-88.7%
LEGN
--

Financial Health

Debt/Equity
ABBV
--
LEGN
0.41
Current Ratio
ABBV
0.72
LEGN
1.96
Quick Ratio
ABBV
0.47
LEGN
1.88

Dividends

Dividend Yield
ABBV
3.05%
LEGN
--
Payout Ratio
ABBV
490.15%
LEGN
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
LEGN BEARISH

LEGN exhibits severe financial instability as evidenced by a critical Piotroski F-Score of 1/9, indicating poor operational health. While the company shows impressive top-line revenue growth of 64.20%, this is offset by consistent earnings misses (average surprise of -66.26% over the last 4 quarters) and a devastating technical trend (0/100). There is a stark disconnect between the bullish analyst target of $57.22 and the actual price performance, which has declined over 41% in the last year. The stock currently behaves as a high-risk speculative asset with failing fundamental health markers.

Strengths
Strong YoY revenue growth of 64.20%
Low Debt/Equity ratio of 0.41
Healthy liquidity with a Current Ratio of 1.96
Risks
Critical Piotroski F-Score (1/9) indicating fundamental weakness
Severe technical breakdown with 0/100 trend score
Consistent failure to meet earnings estimates (1/4 beats in last 4 quarters)

Compare Another Pair

ABBV vs LEGN: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Legend Biotech Corporation (LEGN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile